Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

OBJECTIVE: No evidence of progression or active disease (NEPAD) is a novel combined endpoint defined by the absence of both progression and inflammatory disease activity in primary progressive multiple sclerosis (PPMS). In the placebo‐controlled phase III ORATORIO study (NCT01194570), we investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolinsky, Jerry S., Montalban, Xavier, Hauser, Stephen L., Giovannoni, Gavin, Vermersch, Patrick, Bernasconi, Corrado, Deol‐Bhullar, Gurpreet, Garren, Hideki, Chin, Peter, Belachew, Shibeshih, Kappos, Ludwig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220799/
https://www.ncbi.nlm.nih.gov/pubmed/30155979
http://dx.doi.org/10.1002/ana.25313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220799/
https://www.ncbi.nlm.nih.gov/pubmed/30155979
http://dx.doi.org/10.1002/ana.25313

Ejemplares similares